Ivabradine in Hemodialysed Patients With Increased Heart Rate
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A significant association between resting heart rate (HR) and both all-cause mortality and
cardiovascular mortality has been demonstrated in numerous epidemiologic studies for both the
general population and for patients with cardiovascular disease.
Cardiac disease is the leading cause of death among hemodialysis (HD) patients a recent study
reported that the 48-hr mean HR is an independent predictor of cardiovascular events in
normotensive hemodialysis patients.
Ivabradine, a pure HR lowering agent,acting on If current inhibition has proven beneficial
antianginal effects and mortality reduction linked to HR reduction in ischemic patients.
Aim:
To evaluate the safety and efficacy of ivabradine in normotensive hemodialysed patients with
increased pre-dialysis HR (> 80 bpm)
Phase:
Phase 4
Details
Lead Sponsor:
Second University of Naples University of Campania "Luigi Vanvitelli"